Drug Profile


Alternative Names: FGFRRx; IONIS-FGFR4Rx; ISIS 463588; ISIS-FGFR4Rx; ISIS-FGFRRx

Latest Information Update: 12 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator The University of Queensland
  • Developer Ionis Pharmaceuticals
  • Class Antisense oligonucleotides; Obesity therapies
  • Mechanism of Action Type 4 fibroblast growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Obesity

Most Recent Events

  • 12 Sep 2018 Discontinued - Phase-II for Obesity in USA (SC)
  • 01 Sep 2016 Ionis Pharmaceuticals completes the FGFR4-CS2 trial in Obesity in USA (SC) (NCT02476019)
  • 18 Dec 2015 Isis Pharmaceuticals is now called Ionis Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top